On December 23, the Anhui Provincial Centralized Procurement Platform for Pharmaceuticals announced the Notification of Winning Bids for the Centralized Volume-Based Procurement of Intracranial Stents, Stent Retrievers, and Flow Diverters. AccuMedical's Lattice® Flow Diverter successfully won the bid!<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/12/24/q1pcuju08qs.png"></figure><figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/12/24/h3zymd7wr37.png"></figure>

Great News! Anhui Provincial Centralized Volume-Based Procurement Results Released!

Recently, the Beijing Municipal Bureau of Economy and Information Technology released the Notice on the Announcement of the New List of Beijing Enterprise Technology Centers for 2024. Following a rigorous review, evaluation, and public disclosure of the application materials, AccuMedical was honored to be included on the list.<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/12/25/z54z0mvn9kq.jpg"></figure><figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/12/25/21j2wky39li.png"></figure>The title of "Beijing Enterprise Technology Center" is an authoritative recognition awarded to enterprise technology centers that demonstrate strong innovation capabilities, effective innovation mechanisms, significant leadership, and meet specified criteria. It is a highly prestigious qualification for provincial and ministerial-level R&amp;D platforms, aligning with the requirements of innovation-driven development and economic structural adjustment.As an innovative medical device company dedicated to the field of neurointervention, AccuMedical adheres to a forward-looking R&amp;D principle guided by clinical insights, focusing on independent innovation in core technologies and products. By improving satisfaction for both physicians and patients, reducing surgical risks, and enhancing outcomes, the company continues to lead advancements in neurointerventional treatment.In recent years, AccuMedical has been awarded honors such as "National High-Tech Enterprise" and "National-Level 'Little Giant' Enterprise." Being recognized as a Beijing Enterprise Technology Center further reflects the government’s acknowledgment and affirmation of AccuMedical's R&amp;D innovation capabilities and technological achievements.Moving forward, the company will leverage this recognition as an opportunity to uphold the vision of technological self-reliance and strength. Guided by the corporate value of " Treat, as our own" AccuMedical will continue addressing unmet clinical needs in the field of cerebrovascular diseases, improving the accessibility of innovative medical technologies, and striving to meet the health needs of global cerebrovascular patients.<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/12/30/oc8pqi9f9x.jpg"></figure>

AccuMedical Recognized as a "Beijing Enterprise Technology Center."

In August 2024, the Beijing Municipal Science and Technology Commission&nbsp;， Administrative Commission of Zhongguancun Science Park issued the Notice on the Fund Management Measures to Support Enterprise Innovation Capability Enhancement in the Zhongguancun National Independent Innovation Demonstration Zone.According to Article 9 of the measures, support is provided for the first application of new technologies and products entering the market that address critical gaps in key fields and fill international or domestic technological voids. Eligible projects must feature international or domestic first-of-its-kind innovation, reach leading levels in their respective fields, drive technological advancement, and demonstrate potential for significant economic and social benefits. Additionally, intellectual property rights must be clear, with the enterprise possessing proprietary core technologies for the new products.AccuMedical's Lattice® Flow Diverter was selected for the 2024 First Market Entry of New Technology and Product Program due to its innovative achievements in the field of neurointervention.<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/12/12/itgxzd7ha8b.png"></figure>The Lattice® Flow Diverter, featuring a proprietary mechanical balloon delivery system and MIROR surface modification technology, is the first to extend the indications of flow diverters to the treatment of medium and small vertebral artery aneurysms, addressing a critical clinical gap. Among approved products in its class, Lattice® stands out with its broad indications, exceptional efficacy, and safety advantages. It significantly improves patient outcomes while simplifying and innovating surgical procedures. Its outstanding performance has earned widespread acclaim from physicians in clinical practice.Looking ahead, AccuMedical will continue to increase R&amp;D investment, drive technological innovation and product upgrades in the field of neurointervention, and deliver higher-quality products and services to patients and healthcare professionals worldwide.

Innovation Capability Recognized Again! AccuMedical Selected for the "2024 First Market Entry of New Technology and Product Program" by the Beijing Municipal Science and Technology Commission

Recently, the Ministry of Industry and Information Technology (MIIT) announced the list of the 6th batch of "National Specialized, Refined, Featured, and Innovative 'Little Giant' Enterprises," and AccuMedical Beijing Ltd. was included."Specialized, Refined, Featured, and Innovative" is a concept proposed by the MIIT in the 12th Five-Year Plan for Small and Medium Enterprises, and the "Little Giant" enterprises are its leaders. These enterprises focus on niche markets, possess strong innovation capabilities, have a high market share, control key technologies, and deliver excellent quality and efficiency.AccuMedical, with years of dedication in the field of neurointervention, has developed a comprehensive product line covering both hemorrhagic and ischemic stroke treatment products as well as access assistance devices. The company's self-developed core product, the Lattice® Flow Diverter, has expanded the indications of flow diverters to treat small[S1] &nbsp;and medium-sized vertebral artery aneurysms,&nbsp;filling a critical clinical gap.&nbsp;Compared to large enterprises, specialized and innovative "Little Giant" enterprises may be smaller in size, but they are "small yet sharp" and "small yet specialized," focusing on specific niche areas for the long term. The field of neurointervention, where AccuMedical specializes, is globally recognized as one with high research difficulty, high technical barriers, high clinical value, and large market potential.Currently, cerebrovascular diseases have become one of the leading health threats to middle-aged and elderly individuals, with high disability and mortality rates. Statistics show that approximately 1.5 million people die from cerebrovascular diseases in China every year, with intracranial aneurysms, often referred to as "time bombs," posing an ever-present risk of rupture and causing intracranial hemorrhage. The treatment of complex intracranial aneurysms presents challenges such as high surgical difficulty, high complication rates, and high recurrence rates.Compared to traditional treatments, the Lattice® Flow Diverter developed by AccuMedical is delivered via an interventional approach to the aneurysm-carrying artery. It isolates the aneurysm from the patent artery, redirecting blood flow away from the aneurysm, accelerating thrombosis within the aneurysm, and promoting endothelialization at the aneurysm neck, ultimately repairing the parent artery.The innovation of Lattice lies in its mechanical balloon delivery system, which actively expands the stent from within, ensuring precise deployment at the treatment site and allowing stent retrieval when necessary. This technology successfully reduces surgical complexity and recovery time, marking a new "automation era" in intracranial aneurysm treatment.Currently, Lattice is used in hundreds of hospitals across China, demonstrating exceptional clinical performance. Data shows a 91.4% aneurysm occlusion success rate and only a 0.8% in-stent restenosis rate at 12 months post-surgery. Its clinical application has notably reduced surgical complexity, shortened operation time, and improved patient outcomes.Innovation is the soul of "Specialized, Refined, Featured, and Innovative" enterprises. Only by firmly mastering the core industrial processes and key technologies can small and medium-sized enterprises unleash their tremendous potential. Currently, AccuMedical has applied for more than 118 patents, with 64 granted. These technological achievements provide a solid foundation for AccuMedical’s ongoing innovation and growth in the field of neurointervention.Previously, AccuMedical's innovation capabilities, strong technological accumulation, and clinical application results of its products have been widely recognized. The Lattice® Flow Diverter has been classified by the National Medical Products Administration (NMPA) as an "Innovative Medical Device" and has been fast-tracked through the "Green Channel" for approval. Additionally, in 2022, AccuMedical was recognized as a "Specialized, Refined, Featured, and Innovative" enterprise by Beijing, and in 2023, it was awarded the title of "National High-Tech Enterprise" and recognized by six departments, including the Beijing Science and Technology Commission, Development and Reform Commission, and Economic and Information Technology Bureau, as a new technology and product enterprise.Being selected as a "National Specialized, Refined, Featured, and Innovative 'Little Giant' Enterprise" is further affirmation of AccuMedical's investment in research and development and technological innovation. Moving forward, the company will continue to deepen its focus in the neurointervention field, leading with technological innovation, and providing better products and services to global patients and doctors, striving to drive the new development of China's medical device industry.

AccuMedical Recognized as National "Specialized, Refined, Featured, and Innovative 'Little Giant' Enterprise"

October 17, 2024，the National Medical Products Administration (NMPA) approved the registration of Lattice NEXT, the new generation of Flow Diverter produced by AccuMedical (Beijing) Co., Ltd.<figure class="image image_resized" style="width:597px;"><img src="/uploaded/accumedical/news/content/2024/11/13/glk78wov6t6.png"></figure>

Lattice NEXT, the new generation of AccuMedical’s Intracranial Flow Diverter approved for marketing by the NMPA!

On September 3, 2024, a series of events for the National Drug Safety Publicity Week were held in Beijing. The Medical Device Clinical Trial Management Symposium was hosted by the Department of Medical Device Registration of the National Medical Products Administration (NMPA), organized by the Beijing Municipal Drug Administration, and co-organized by Peking University's School of Medicine and Peking University Third Hospital. Lei Ping, a member of the NMPA Party Leadership Group and Deputy Administrator, attended the meeting and delivered a speech. Cao Wei, Director of the Beijing Municipal Drug Administration, also attended and gave a speech, while Li Dachuan, Deputy Director of the Medical Administration Department of the National Health Commission, and Lin Hang, Vice Mayor of Haidian District, participated in the event.<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/09/13/lrnkr8r8zjh.png"></figure>As a representative of domestic innovative medical device companies, AccuMedical was invited to attend the symposium and showcase its products.The symposium, themed "Strengthening Clinical Trial Quality Management and Promoting Medical Device Innovation and Development," aimed to publicize the policies and regulations regarding medical device clinical trial management, create a communication platform for clinical trial institutions, sponsors, researchers, and regulatory authorities, and promote the high-quality development of the medical device industry.Lei Ping, a member of the NMPA Party Leadership Group and Deputy Administrator, attended the symposium and delivered a speech. He emphasized that clinical trials are a critical method for evaluating the safety and effectiveness of medical devices. The NMPA will continue to improve the regulatory framework, strengthen the management of clinical trial institutions, and enhance the quality of clinical trials, working together with all stakeholders to foster a healthy clinical trial ecosystem.Cao Wei, Administrator of the Beijing Municipal Drug Administration, stated that the Bureau would implement the NMPA's requirements and plans in depth, coordinating development and safety. On the one hand, they will steadily promote "dual filing" for clinical trials and continually strengthen "dual inspections" to reduce risks associated with clinical trial processes. On the other hand, they will collaborate with multiple departments to optimize the business environment, improve evaluation and approval efficiency, and boost the high-quality development of the medical device industry.<figure class="image"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/09/13/wjss6hxroym.jpg"></figure>At the symposium, AccuMedical showcased its core product, the Lattice® Flow Diverter. Lei Ping, Deputy Administrator of the NMPA, Cao Wei, Administrator of the Beijing Municipal Drug Administration, as well as other drug administration leaders and experts, including Fu Wei, Director of Peking University Third Hospital, visited AccuMedical's booth and inquired about the product's R&amp;D and clinical applications.The Lattice® Flow Diverter is the first flow diverter to extend the indications to the treatment of medium and small vertebral artery aneurysms. By creatively integrating a mechanical balloon delivery system and MIROR surface modification technology, it represents a novel surgical approach for intracranial aneurysm treatment, which has rapidly developed and matured internationally over the past decade.Compared to traditional intrasaccular coiling procedures, AccuMedical's Lattice® Flow Diverter streamlines the treatment process for aneurysms. Its unique mechanical balloon system enhances precision and ensures smooth stent deployment, effectively addressing challenges such as stent kinking and vascular injury commonly seen in traditional surgeries. Additionally, the MIROR surface modification technology further enhances surgical safety and patient outcomes.Clinical data demonstrates that Lattice achieves a 91.4% aneurysm occlusion success rate and an in-stent restenosis rate of only 0.8% at 12-month post-surgery. By significantly reducing surgical complexity, it enhances the accessibility of intracranial aneurysm treatments. Today, Lattice is not only used in renowned top-tier hospitals in major cities but has also been widely adopted by county-level hospitals.Thanks to its deep technical foundation and continuous innovation in the neurointervention field, AccuMedical was recognized as a "Specialized, Refined, Featured, and Innovative" small and medium-sized enterprise by Beijing in 2022 and awarded "National High-Tech Enterprise" status in 2023.At the National Drug Safety Publicity Week opening ceremony, the NMPA stated that, in recent years, it has strictly implemented General Secretary Xi Jinping’s "Four Strictest" requirements, focusing on high-efficiency regulation to ensure high-level safety and promote high-quality development. China's pharmaceutical management regulatory system has been continuously improved, drug safety remains generally stable, and the pace of market approval for innovative drugs and medical devices has accelerated. The NMPA has also made solid progress in strengthening drug regulatory capabilities, effectively protecting and promoting public health.As an innovative company in the neurointervention field, AccuMedical aims to actively contribute to national medical innovation, ensuring high-level safety and the high-quality development of the industry, continuing to drive "genuine innovation and practical application" in the field of Chinese-made neurointerventional medical devices, and safeguarding public health and people’s lives with better products.

AccuMedical Invited to Attend the "National Drug Safety Publicity Week" Medical Device Clinical Trial Management Symposium

From August 9 to 11, Beijing hosted a major medical event&nbsp;– the 30th China International Medical Instrument and Equipment Exhibition &amp; Technical Exchange (China-Hospeq 2024). At this event, AccuMedical showcased its innovative product, the Lattice® Flow Diverter, showcasing the latest breakthroughs in neurointervention.<figure class="image"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/08/15/uvp723re2eq.jpg"></figure>&nbsp;A Feast of TechnologyChina-Hospeq 2024 was more than an exhibition; it was a platform for global medical experts to exchange ideas and share experiences. The event was hosted by the International Exchange and Cooperation Center of the National Health Commission, with over 200 high-quality enterprises from more than 10 countries and regions, including China, Germany, the United States, the Netherlands, and Sweden. These companies displayed products, technologies, and the latest solutions to address the health needs of various countries. Participants discussed ways to optimize the global medical trade and investment environment, promote deeper cooperation between Central Asia and China, and support regional health and well-being.At this international event, AccuMedical, as a representative in the field of neurointervention, attracted the attention of many domestic and international scholars and experts with its innovative Lattice® Flow Diverter technology.<figure class="image"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/08/15/5smxsw3xhwd.jpg"></figure><figure class="image"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/08/15/pd4tzfs0n9q.jpg"></figure><figure class="image"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/08/15/5jfwafbdxqy.jpg"></figure>Intracranial aneurysms, often referred to as "ticking time bombs" in the brain, have posed significant challenges for surgeons and patients due to the complexity of traditional treatment procedures and slow post-operative recovery over the past decades. The Lattice® Flow Diverter provides a new solution to this problem. For the first time, it extends the indications for flow diverters to include the treatment of medium and small vertebral artery aneurysms, addressing a critical gap in clinical needs.&nbsp;The innovative mechanical balloon system equipped on Lattice effectively addresses &nbsp;issues such as stent kinking and opening during surgery, ensuring precise positioning and smooth deployment. Additionally, the application of the MIROR surface modification technology resolves complications thay may arise from metal oxides on the surface of woven stents, significantly enhancing surgical safety.&nbsp;Bringing Chinese Innovation to the WorldClinical data shows that Lattice® Flow Diverter achieves a high aneurysm occlusion rate of 91.4% at 12 months post-operation, with an in-stent restenosis rate of only 0.8% at 12 months, which demonstrates Lattice’s superior surgical safety and favorable prognosis. Its unique design not only reduces surgical complexity but also improves the accessibility of intracranial aneurysm treatment.AccuMedical has not only made breakthroughs with Lattice® but also offers a product line that covers interventional devices and access devices for the treatment of hemorrhagic and ischemic strokes. To date, the company has filed 118 patent applications, with 63 granted, and seven products have been approved and entered the commercialization phase.<figure class="image"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/08/15/ko5c8nu9gge.jpg"></figure><figure class="image"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/08/15/nksl9st7p0k.jpg"></figure><figure class="image"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/08/15/jk9rwx2p7i.jpg"></figure><figure class="image"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/08/15/ojcnjb8r8up.jpg"></figure>China-Hospeq 2024 provided a global platform for domestic medical enterprises like AccuMedical. With frequent appearances on international medical exchange platforms, AccuMedical, as a new force in China’s neurointervention field, is injecting new vitality into the global research and development of cerebrovascular diseases.On the endless journey of exploring healthcare, the Lattice® Flow Diverter is just the beginning for AccuMedical. With more Chinese enterprises joining in, we have reason to believe that the future healthcare field will be even more exciting, with an increasing number of innovative products bringing more hope and possibilities to human health. Let us look forward to seeing the power of Chinese medical innovation shining brightly on the global stage.

"Exploring New Frontiers in Healthcare: AccuMedical's Lattice® Shines at China-Hospeq 2024"

“As a Chinese doctor, I deeply feel the increasing global attention and respect for China’s experiences and perspectives. Over the past 30 years, China has transformed from a follower to gradually aligning with international standards in the field of neurointervention. Through extensive research and innovation, China has contributed new evidence, devices, and experiences, which are of significant importance to scholars worldwide.” This was stated by Professor Liu Jianmin, Director of the Cerebrovascular Disease Center at the First Affiliated Hospital of the Naval Medical University (Shanghai Changhai Hospital), during a live interview at the World Live Neurovascular Conference (WLNC) in Istanbul. During this world-class academic exchange in the neurointervention field, Professor Liu Jianmin’s team demonstrated the Lattice® Flow Diverter, developed by AccuMedical, showcasing this innovative tool that directly addresses the clinical challenges of intracranial aneurysm treatment.<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/05/15/sqxn9ga03fc.png"></figure>&nbsp;Unraveling the Global Challenge of Intracranial Aneurysm TreatmentStroke is now the second leading cause of death worldwide, with China experiencing particularly high incidence rate, especially hemorrhagic strokes caused by intracranial aneurysms. Known as "ticking time bombs" in the brain, intracranial aneurysms are abnormal bulges in the arterial walls &nbsp;that can rupture at any time, leading to life-threatening intracranial hemorrhages. Data reveals that the prevalence of unruptured aneurysms in China’s population aged 35-75 reaches 7.0%, affecting nearly 100 million individuals. Once ruptured, the fatality rate from the first hemorrhage is around 35%, climbing to 60%–80% in case of recurrent bleeding.Faced with this high-risk condition, the medical community has been actively exploring new treatment approaches. Traditional craniotomies often impose greater financial, surgical, and psychological burdens on patients, with long recovery periods. However, advancements in neurointerventional technology have introduced a minimally invasive approach to treat unruptured aneurysms. Through vascular reconstruction with flow diverters, early intervention is now possible to “defuse the bomb” before rupture.The Lattice® Flow Diverter by AccuMedical, showcased at the WLNC, is one such “defusing tool”. Public information indicates that Lattice® is the first flow diverter of its kind to utilize mechanical balloon delivery technology and surface modification technology. Approved in October 2022 under the National Special Review Procedures for Innovative Medical Device (“Green Channel”), it is indicated for various aneurysms in the internal carotid and vertebral artery. Its approval includes the broadest indication in its class, making it the first product to extend indications to medium and small vertebral artery aneurysms.Clinical data highlights its impressive efficacy, with a 91.4% aneurysm occlusion success rate and only a 0.8% in-stent restenosis rate at 12 months post-surgery. During a live demonstration at WLNC, Professor Yang Pengfei from the First Affiliated Hospital of the Naval Medical University (Shanghai Changhai Hospital) introduced Lattice's structural and performance features, shared findings from LIFE pre-market clinical study, and demonstrated its operational techniques. The presentation garnered significant interest and attention from attending international experts.<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/05/15/ahgl5blp4h.png"></figure>In the live interview in Istanbul, Professor Liu Jianmin stated, "Innovation in China's neurointervention field is becoming increasingly prominent. This year, the surgeries we broadcast primarily used domestically manufacutred devices. Among them are globally leading devices such as the Lattice® Flow Diverter, whose innovative design surpasses existing products in many aspects. For example, it features a mechanical balloon delivery system with radiopaque markers and the MIROR surface modification technology. The mechanical balloon delivery system has an automatic expansion function, effectively resolving common issues like poor stent opening and inadequate wall apposition when deploying flow diverters in curved vessels. This innovative design simplifies the use of flow diverters in complex vescular scenarios.""Lattice®, through multiple groundbreaking technological innovations, has greatly reduced the surgical complexity for clinicians, shortened operation times, and improved patient recovery rates and surgical safety, ushering intracranial aneurysm treatment into an ‘automatic era’,” a representative from AccuMedical stated in a recent interview with CCTV News.The Lattice® Flow Diverter incorporates an innovative mechanical balloon system that effectively addresses challenges such as stent kinking and opening failure, and vascular damage caused by complex operations. This ensures precise positioning and smooth deployment, advancing intracranial aneurysm treatment into the "automatic" era. Additionally, with its advanced material selection and processing techniques, the MIROR surface modification technology resolves issues related to ischemic complications and cytotoxicity caused by metal oxides on woven stent surfaces, significantly enhancing surgical safety.&nbsp;China’s Self-developed Innovation Reaches the International StageThe WLNC is one of the largest and most internationalized neurointervention exchange platforms in the world. AccuMedical, as a representative of Chinese innovative medical devices, participated in this international event, showcasing the strength of China’s "new quality productive forces." In the past, due to the high technical barriers in stroke treatment, the development of neurointervention in China was limited. However, with continuous innovation and development by companies like AccuMedical, the trend of domestic production in the neurointervention field is emerging.According to Frost &amp; Sullivan data, from 2017 to 2022, the number of intracranial aneurysm interventional treatments in China increased from 44,000 to 84,000, with a compound annual growth rate (CAGR) of 13.8%. It is expected that by 2028, the number of procedures will reach 912,000, with a CAGR of 48.9%. This provides significant growth potential for domestic medical devices."Developing new quality productive forces&nbsp;cannot simply be about benchmarking foreign products. AccuMedical aims to break the 'imitation-following' technological path and continue investing in innovative R&amp;D to achieve 'true innovation and practical use' in the field of domestically produced neurointerventional medical devices," said an AccuMedical representative in a media interview.Public information shows that AccuMedical holds more than 100 domestic and international patents and has dual R&amp;D centers in China and the United States. With deep technical expertise and continuous innovation, AccuMedical has been recognized as a "Specialized, Refined, Featured, and Innovative" small and medium-sized enterprise by Beijing, a National High-Tech Enterprise, and is also one of the drafting units for the national standard for neurovascular thrombectomy stents. In addition to the Lattice® Flow Diverter showcased at the WLNC, AccuMedical's product line covers interventional devices and access devices for both hemorrhagic and ischemic stroke treatment, with seven products approved and entering the commercialization stage.<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/05/15/06m5kes34ze.png"></figure>&nbsp;A Promising Future for China’s Innovative Medical DevicesProfessor Liu Jianmin, in his live interview at the conference in Istanbul, commented, "The display of these innovative products indicates that China has transitioned from a follower to a contributor, researcher, and innovator in the field of neurointervention. We are now making important contributions to global neurointervention research and development. We are providing the latest high-level evidence, new devices, new concepts, and relevant experiences. I believe that in the post-pandemic era, as international exchanges become more routine, China's voice and contributions in neurointervention will have an increasingly significant global impact."

AccuMedical's Lattice® Debuts at WLNC, ushering intracranial aneurysm treatment into the "Automatic Mode" Era

Recently, the "Paracurve® Radial Access Guiding Catheter," independently developed by AccuMedical (Beijing) Co., Ltd., was approved for registration by the National Medical Products Administration (NMPA). The product has obtained a Class III medical device registration certificate with the registration number: NMPA 20243030848.This product is designed for introducing interventional devices into neurovascular, peripheral, and coronary arteries via the radial artery. It includes a guiding catheter and a selective catheter.AccuMedical is a commercialized innovative medical device company specializing in the field of neurointervention. Founded in 2017, AccuMedical is headquartered in Beijing with dual R&amp;D centers in China and the United States. AccuMedical has developed comprehensive businesses including R&amp;D, production, and marketing of neurointerventional devices for the treatment of hemorrhagic and ischemic strokes. Our mission is to offer a whole set of innovative solutions to a global population of cerebrovascular disease patients and physicians. As of March 2024, the company has filed 111 patent applications, with 65 patents granted.

AccuMedical’s Paracurve® Radial Access Guiding Catheter Approved for Marketing by NMPA

<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/05/11/9mym1wv8akl.jpg"></figure>From April 25 to 29, 2024, the Zhongguancun Forum Annual Conference was held in Beijing, with the theme "Innovation: Building a Better World."At this forum, major achievements in four key areas were highlighted: the cutting-edge frontier of global science and technology, the main economic battlefield, national strategic needs, and public health and people's lives. A series of world-class achievements and "cutting-edge technologies" innovations made their debut, including Nobel Laureate in Physiology or Medicine Barry Marshall sharing his views on "Curiosity-Driven Research," Fields Medalist Shing-Tung Yau discussing "Women and Scientific Development," and two Turing Award winners exploring the frontiers of artificial intelligence.At this national and international event, AccuMedical's core product, the Lattice® Flow Diverter, was showcased alongside the latest high-end medical innovations in China, earning recognition and praise from national and municipal leaders.<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/05/11/ltz8n8f1npj.jpg"></figure>Currently, AccuMedical holds over 100 domestic and international patents. Its neurointervention products cover all interventional devices and related access devices involved in the treatment of hemorrhagic and ischemic stroke. Six products have been approved and are rapidly progressing toward registration and commercialization.With deep technical expertise and continuous innovation in the neurointervention field, AccuMedical was named a "Specialized, Refined, Featured, and Innovative" small and medium-sized enterprise in Beijing in 2022 and a National High-Tech Enterprise in 2023.AccuMedical insists on integrating medicine and engineering to truly meet clinical patient needs. The Lattice® Flow Diverter is a new tool for the treatment of intracranial aneurysms, approved through the National Medical Products Administration's (NMPA) special review procedure for innovative medical devices. It is the first to expand the indication of flow diverters to treat small- and medium-sized vertebral artery aneurysms. It is now being used in many hospitals across China and has received high recognition from surgeons.<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/05/11/441gdh76wrf.jpg"></figure>Intracranial aneurysms, often called the brain’s "ticking time bombs" have traditionally been treated through craniotomy, a procedure with high risks and long recovery time. The Lattice® Flow Diverter, with its material and structural innovations, has ushered intracranial aneurysm treatment into an easier “automatic era”.Thanks to multiple groundbreaking innovations, the Lattice® Flow Diverter significantly enhances surgical efficacy and safety. Its mechanical balloon delivery system effectively minimizes vascular injury risks during procedures, ensures precise stent positioning, and achieves optimal wall apposition, thereby shortening surgery time and reducing complexity. Additionally, the MIROR surface modification technology effectively addresses issues with ischemic complications and cytotoxicity caused by metal oxides on woven stent surfaces, greatly improving surgical safety.Clinical data highlights its effectiveness in improving patient outcomes: at 12 months post-surgery, the Lattice® Flow Diverter achieves a 91.4% success aneurysm occlusion rate and an in-stent restenosis rate of just 0.8%.By greatly reducing the difficulty of treating past complex cases, the Lattice® Flow Diverter is making a significant contribution to improving public health and people's lives. This is the key significance of developing new quality productive forces in the medical field.<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/05/11/ohixa2mq5g.jpg"></figure>During an interview at the forum, AccuMedical’s CEO stated, “Developing new quality productive forces cannot simply be about benchmarking foreign products. AccuMedical aims to break the 'imitation-following' technological path and continue investing in innovative R&amp;D to achieve ‘true innovation and practical use’ in the field of neurointerventional medical devices, continuing to produce better products to safeguard public health.”

AccuMedical Shines at 2024 Zhongguancun Forum with Breakthrough Innovations, Capturing CCTV's Attention

On January 19, 2024, the U.S. Food and Drug Administration (FDA) approved the 510(k) application of Cosine® Distal Access Catheter produced by AccuMedical (Beijing) Co., Ltd. The approval information has been officially published in the FDA's premarket notification database.The FDA approval of the Cosine® Distal Access Catheter signifies that its safety and effectiveness have been recognized by U.S. regulatory authorities, offering patients more efficient and safer treatment options.<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/12/16/q0o8kuhm71e.png"></figure>The Cosine® Distal Access Catheter is designed for use in interventional procedures, facilitating the delivery of interventional devices in peripheral and neurovascular systems. It features a wide range of sizes, excellent torque control, minimal vascular irritation, and superior radiopacity, making it suitable for diverse surgical approaches.<figure class="image image_resized" style="width:599px;"><img src="https://www.accumedical.com/uploaded/accumedical/news/content/2024/12/16/fzkrt1zb02f.png"></figure>AccuMedical has been dedicated to the neurointervention field for many years. This FDA 510(k) clearance not only opens broader international markets for the company but also provides more comprehensive neurointerventional solutions for global cerebrovascular disease patients and physicians.

AccuMedical’s Cosine® Distal Access Catheter Approved for Marketing by FDA

<figure class="image"><img src="/uploaded/accumedical/news/content/2024/11/01/epo361bbk8d.png"></figure>&nbsp;Recently, the National Medical Products Administration (NMPA) has approved the registration of the innovative product Intracranial Flow Re-Direction System produced by AccuMedical (Beijing) Co., Ltd.Lattice is an innovative flow diverter with mechanical balloon delivery system, which actively assists the opening of the stent from inside. The implant is made of cobalt-chromium alloy, which provides sufficient radial force and excellent wall apposition with the expansion of the mechanical balloon. Both the implant and mechanical balloons are treated with surface modification named MIROR (Metal Interface Reassembly for Optimizing Restenosis) technology, in order to reduce thrombogenicity and promote endothelialization.Lattice is intended for use in adult patients with wide-neck (aneurysm neck width ≥ 4mm or aneurysm/body ratio &lt; 2) non-ruptured intracranial aneurysms in the internal carotid artery (petrous to terminal) and vertebral artery, with vessel diameters ≥ 2.0mm and ≤ 5.6mm.Approved for marketing, Lattice will offer a theraupeutic treatment option for the physicians and patients.&nbsp;<figure class="image"><img src="/uploaded/accumedical/news/content/2023/11/16/teozl94005.png"></figure>&nbsp;Source:https://www.nmpa.gov.cn/yaowen/ypjgyw/ylqxyw/20221026140656139.html

Recently, the National Medical Products Administration (NMPA) has approved the registration of the innovative product Intracranial Flow Re-Direction System produced by AccuMedical (Beijing) Co., Ltd.

News